SCHEMBL3309968

SCHEMBL3309968

O=C1CCc2cc(-c3cccc(C(=O)N4CCOCC4)c3)ccc2N1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.60
CRBN Q96SW2 4/20 0.56
MEN1 O00255 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
ERN1 O75460 2/20 0.54
ABL1 P00519 2/20 0.52
PLK4 O00444 1/20 0.50
JAK2 O60674 1/20 0.50
MAP4K4 O95819 1/20 0.50
ROS1 P08922 1/20 0.50
FGFR1 P11362 1/20 0.50
FLT1 P17948 1/20 0.50
MARK3 P27448 1/20 0.50
FLT4 P35916 1/20 0.50
KDR P35968 1/20 0.50
FLT3 P36888 1/20 0.50
CLK2 P49760 1/20 0.50
CSNK1G2 P78368 1/20 0.50
MAP4K2 Q12851 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7325238 0.87 CRBN (0.58) HPGDCRBNKMT2APDE3BPDE3A
SCHEMBL3312591 0.78 TDP2 (0.60) CRBNRAB9ABRD4PDE3BPDE3A
SCHEMBL3309000 0.78 TDP2 (0.60) CRBNRAB9ABRD4PDE3BPDE3A
SCHEMBL23143502 0.77 CRBN (0.69) HPGDCRBNABL1BRD4PDE3B
SCHEMBL29899562 0.77 CRBN (0.69) HPGDCRBNABL1BRD4PDE3B
SCHEMBL6214174 0.76 POLB (0.53) HPGDCRBNKMT2AOTUD7BL3MBTL1
SCHEMBL11045067 0.76 CRBN (0.57) CRBNMEN1KMT2APDE3BPDE3A
SCHEMBL11045054 0.76 CRBN (0.62) HPGDCRBNRAB9APDE3BPDE3A
SCHEMBL28860346 0.76 HPGD (1.00) HPGDMEN1RAB9AKMT2AERN1
SCHEMBL4245858 0.75 HPGD (0.74) HPGDMEN1RAB9AKMT2AERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952007-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-02-10 US claimed
US-20130096122-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-04-18 US claimed
WO-2010074807-A1 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-07-01 WO claimed
US-20100113514-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8952007-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-02-10 US disclosed
US-8664379-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-03-04 US disclosed
US-20130096122-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-04-18 US disclosed
WO-2010074807-A1 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-07-01 WO disclosed
US-20100113514-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113514-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, KCNH3 HPGD 2116/4885CRBN 3624/4885MEN1 1590/4885
US-20130096122-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, CACNA1E HPGD 1985/4885CRBN 3956/4885MEN1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.